Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Dermatology Life Quality Index"

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Dermatology Life Quality Index | 01/10/2026 | By News Bureau

Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026

Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.

Dermatology Life Quality Index | 12/02/2026 | By News Bureau | 490

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members